Reuters logo
BRIEF-Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints
2017年4月17日 / 下午12点32分 / 7 个月前

BRIEF-Oncomed's Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints

April 17 (Reuters) - Oncomed Pharmaceuticals Inc

* Oncomed’s Phase 2 trial of Tarextumab in small cell lung cancer does not meet endpoints

* Oncomed Pharmaceuticals Inc - trial did not meet its primary endpoint of progression-free survival or secondary endpoints

* Also announces discontinuation of brontictuzumab Phase 1B study Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below